CytRx Corporation

Company Snapshot: CytRx Corporation

Last Change Volume High Low

Company Overview

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated under a special protocol assessment a pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and recently announced that it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. CytRx is currently evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. CytRx has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to expand its pipeline of oncology candidates using its recently-announced LADR(tm) (Linker Activated Drug Release) technology platform at its laboratory facilities in Freiburg, Germany. The LADR(tm) technology is based on novel linkers that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites.

Featured Documents

Client News

  1. Oct 16 2017 CytRx Corporation Announces Outcome of Nasdaq Hearing
  2. Oct 12 2017 CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.
  3. Oct 4 2017 Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split
  4. Oct 2 2017 CytRx Corporation Provides Business Update and Highlights Future Plans